These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26149736)

  • 1. The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.
    Fabris M; Quartuccio L; Fabro C; Sacco S; Lombardi S; Ramonda R; Biasi D; Punzi D; Adami S; Olivieri I; Curcio F; De Vita S
    Pharmacogenomics J; 2016 Jun; 16(3):238-42. PubMed ID: 26149736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
    Polo Y La Borda J; Campos J; Sanz J; Andréu JL; Mulero J; Sánchez A
    Int J Rheum Dis; 2019 Aug; 22(8):1529-1537. PubMed ID: 31119895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
    Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
    Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.
    Cabaleiro T; Prieto-Pérez R; Navarro R; Solano G; Román M; Ochoa D; Abad-Santos F; Daudén E
    Pharmacogenomics J; 2016 Aug; 16(4):336-40. PubMed ID: 26194362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.
    Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G
    Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
    Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNFs in axial spondyloarthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):10-3. PubMed ID: 25572548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
    Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of extreme patient-reported outcome in early spondyloarthritis and its impact on the effect of TNF-α blockers treatment.
    Meghnathi B; Claudepierre P; Dougados M; Moltó A
    Clin Exp Rheumatol; 2018; 36(6):1043-1048. PubMed ID: 30183594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
    Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
    Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.
    Moltó A; Paternotte S; Claudepierre P; Breban M; Dougados M
    Arthritis Rheumatol; 2014 Jul; 66(7):1734-44. PubMed ID: 24623678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Gene Polymorphism in Children With Idiopathic Nephrotic Syndrome.
    Midan DAR; Elhelbawy NG; Habib MSE; Ahmedy IA; Noreldin RI
    Iran J Kidney Dis; 2017 Nov; 11(6):414-421. PubMed ID: 29190601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.
    Lekpa FK; Poulain C; Wendling D; Soubrier M; De Bandt M; Berthelot JM; Gaudin P; Toussirot E; Goupille P; Pham T; Sellam J; Bruckert R; Paul M; Farrenq V; Claudepierre P;
    Arthritis Res Ther; 2012 Mar; 14(2):R53. PubMed ID: 22404969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.
    Fagerli KM; van der Heijde D; Heiberg MS; Wierød A; Kalstad S; Rødevand E; Mikkelsen K; Kvien TK; Lie E
    Rheumatology (Oxford); 2014 Jun; 53(6):1087-94. PubMed ID: 24501243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis.
    Spadaro A; Lubrano E; Marchesoni A; Cauli A; Cantini F; Carotti M; D'Angelo S; Grassi W; Lapadula G; Macchioni P; Mathieu A; Punzi L; Ramonda R; Salaffi F; Salvarani C; Scarpa R; Olivieri I
    Clin Exp Rheumatol; 2014; 32(4):465-70. PubMed ID: 24850468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spondyloarthritis: from unifying concepts to improved treatment.
    Paramarta JE; Baeten D
    Rheumatology (Oxford); 2014 Sep; 53(9):1547-59. PubMed ID: 24369419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort.
    Wallis D; Thavaneswaran A; Haroon N; Ayearst R; Inman RD
    Rheumatology (Oxford); 2015 Jan; 54(1):152-6. PubMed ID: 25125593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?
    Goupille P; Wendling D
    Joint Bone Spine; 2024 May; 91(3):105662. PubMed ID: 37977524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.